Post

Innovent eyes third-line nod for gastric cancer ADC on Phase III PFS hit

Takeda’s $11.4bn bet on assets from Chinese biotech, Innovent Biologics, is showing early signs of paying off, as the latter …
ASCO 2026: darovasertib raises the bar in metastatic uveal melanoma

At the American Society of Clinical Oncology (ASCO) Annual Meeting 2026, held on 29 May - 2 June, primary results …
Otsuka’s Voyxact preserves kidney function at 12 months

Otsuka Pharmaceutical’s Voyxact (sibeprenlimab-szsi) has preserved kidney function for 12 months in patients with primary IgA nephropathy (IgAN) in a …
ASCO26 Podcast: an analyst rundown of the best readouts and key trends

While the 2026 American Society of Clinical Oncology (ASCO) conference may be over for another year, the editorial team at …
Novartis reports positive results from Phase III ALIGN trial for IgAN

Novartis has announced final results from the Phase III ALIGN study, highlighting that Vanrafia (atrasentan) slows kidney function decline versus …

First patient dosed in Onchilles’ Phase I/II trial of N17350

Onchilles Pharma has dosed the first patient in its Phase I/II clinical trial of N17350, the lead tumour-directed therapeutic candidate, …
ASCO 2026: Interim data released for upcoming BRAF and RAS mCRC therapies

Several abstracts and data presentations on emerging clinical research in metastatic colorectal cancer (mCRC) prompted expert interest and discussion at …
ASCO 2026: Novel CD5 directed CAR-T therapy for T-ALL/PTCL shows mixed response

Patients with T-cell acute lymphoblastic leukaemia (T-ALL) and the closely related peripheral T-cell lymphoblastic lymphoma (PTCL) represent a group with …
Argenx’s Vyvgart shows durability in myositis and Sjögren’s

Argenx’s Vyvgart (efgartigimod alfa-fcab) shows lengthy benefit for myositis and Sjögren’s disease, setting up its anticipated Phase III readouts. The data …
EMA and AMA collaborate on Ebola trials amid public health emergency

The European Medicines Agency’s (EMA’s) emergency task force (ETF) is engaging with the African Medicines Agency (AMA) to plan clinical …
Massive Bio and Optellum partner on early NSCLC detection and trials

Massive Bio and Optellum have formed a partnership to integrate early detection of non-small cell lung cancer (NSCLC) with access …
J&J’s nipocalimab meets primary endpoint in Phase II JASMINE study

Johnson & Johnson (J&J) has reported that its monoclonal antibody, nipocalimab, met the primary endpoint in the Phase II JASMINE …
Rezolute’s stock up on interim Phase III tumour HI data

Rezolute’s second Phase III trial of ersodetug, this time in tumour hyperinsulinism (HI), is yielding more promising data, prompting the company’s …
Gilead eyes PBC expansion for Livdelzi on positive one-year data

Gilead Sciences has debuted 52-week data from a late-stage study on its primary biliary cholangitis (PBC) therapy, Livdelzi (seladelpar), demonstrating …
Inipharm commences dosing in INI-822 trial for MASH

Inipharm has started dosing in a 12-week proof-of-concept clinical study evaluating its oral hydroxysteroid 17-beta-dehydrogenase 13 (HSD17B13) inhibitor, INI-822, in …